Cell line · CVCL_0126
Papers86
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 86
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The YTHDC1/HECW1/SMAD7 axis drives cisplatin resistance in bladder cancer. | Transl Androl Urol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| m5C-Modified tRF3b-CysGCA-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genomic comparison and phenotypic characterization of Pseudomonas aeruginosa isolates across environmental and diverse clinical isolation sites. | mSystems | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened. | FASEB J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial-Mesenchymal Transition Pathway. | Cancer Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| XPC Deficiency Activate Cisplatin-Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1-Mediated Ubiquitination of the p53 Protein. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A smart gene circuit for precise regulation of tumor cell behavior. | Synth Syst Biotechnol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Long Noncoding RNA DGUOK-AS1 Promotes Bladder Cancer Progression by Enhancing EFTUD2 Stability. | Cancer Res Treat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin. | J Exp Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Utility of Tumor Suppressor E2F Target Gene Promoter Elements to Drive Gene Expression Specifically in Cancer Cells. | Cells | 2025 | Its Methods give the RRID and name the line | PubMed | |
| FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression. | Hum Mutat | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Neutrophil extracellular traps-STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer. | J Immunother Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mapping genetic and phenotypic diversity of Pseudomonas aeruginosa across clinical and environmental isolation sites. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0126/papers